“NextUp” is a weekly NextHealth PHL feature that highlights the local leaders, organizations and research shaping the Greater Philadelphia region’s life sciences ecosystem. Email ccunningham@phillymag ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Gilead is soaring to new heights in the CAR-T therapeutics sector, acquiring in vivo cell therapy specialist Interius BioTherapeutics via its subsidiary Kite for $350m. The deal will integrate ...
PHILADELPHIA, May 18, 2021 /PRNewswire/ — Interius BioTherapeutics, a preclinical stage gene therapy company developing a paradigm-shifting platform for in vivo cell-specific gene delivery, today ...
Kite Pharma, a Gilead Sciences subsidiary, has entered into a binding agreement to acquire Interius BioTherapeutics—a privately held biotechnology firm—for $350 million in cash. The strategic ...
The cell and gene therapy field is experiencing a renaissance of sorts, with about a dozen products approved in the past few years. However, most of these therapies require physicians to collect and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results